J Korean Ophthalmol Soc.  1978 Mar;19(1):9-18.

The Influence of Enzyme (Urokinase(R)) and Liquefaction of Vitreous on Absorption of Simulated Vitreous Hemorrhages

• Lee TS

Abstract

This investigation was undertaken to study the mechanisms involved in the absorption of blood from the vitreous, and was divided into following experimental groups: A) Eyes injected with 0.1 cc whole blood (7 eyes). B) Eyes injected with 0.1 hemolyzed blood (7 eyes). C) Eyes injected with 0.1 cc (12IU/0.1ml) urokinase solution after 0.1 cc whole blood injection (7 eyes). D) Eyes injected with 0.1 cc whole blood after 0.5 cc vitreous aspiration (7 eyes). E) Combined group of C) and D) (7 eyes). In each experimental group. simulated vitreous hemorrhages were induced in rabbits by intravitreal injection of 0.1 ml autologous radioactive chronim (51Cr) tagged blood through the pars plana at 12 o'clock position. Thereafter, the author counted the rates of change of radioactivity of the eyes with a scintillation counter everyone day during 10 days and their percentages were obtained. The results obtained were as follows: 1) The average rate of removal of whole blood group from the vitreous cavity(1/2-life; time required for 50% of the injected radioactivity to disappear) was approximately 1/5 times those of hemolyzed group and combined group, and 2/5 times that of urokinase group, 3/5 times that of vitreous aspiration group. 2) The average rate of removal of w hloe blood group from the vitreous cavity (3/4-life; time required for 75% of the injected radioactivity to disappear) was approximately 1/3 times that of hemolyzed blood, and 1/5 times those of urokinase group and combined group. 3) From those results, it was concluded that diffusion of blood elements and hemolysis, alternation of vitreous structure itself were closely related to the absorption of vitreous hemorrhage.

MeSH Terms

Absorption*
Diffusion
Hemolysis
Intravitreal Injections
Rabbits
Radioactivity
Scintillation Counting
Urokinase-Type Plasminogen Activator
Vitreous Hemorrhage*
Urokinase-Type Plasminogen Activator